Gene effects on cholesterol drug for people with diabetes or heart risk
Part of Hormones & metabolism clinical trials.
This study looks at how your genes affect the way your body responds to rosuvastatin, a drug that lowers cholesterol. It aims to find the best dose for you based on your genetic makeup.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 20 and 79 years old.
- You have diabetes or heart or blood vessel disease, along with at least three of these: belly obesity, high triglycerides, low HDL (good cholesterol), high blood pressure, or high fasting blood sugar.
- Your cholesterol levels are within a certain range that qualifies for treatment.
- You have not had bad reactions to statin or fibrate drugs before.
- You are not pregnant or breastfeeding, and do not have severe health issues like uncontrolled diabetes, liver problems, or heart failure.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two cholesterol-lowering medicines (rosuvastatin and fenofibrate) for people with diabetes or metabolic syndrome who have unhealthy cholesterol levels. The goal is to see if taking both together works better than taking one alone.
This study looks at how your genes affect a new medicine that helps lower cholesterol when statins alone aren't enough. If you join, you'll add this medicine to your current statin to see if it helps you reach your cholesterol goals.
This early study tests whether “liver fat” changes how a statin (rosuvastatin) works in children and teens. It may help doctors choose safer or more effective dosing in kids based on biology and a specific genetics marker.
This is a research study testing whether specific gene changes are linked to fatty liver and a cholesterol pattern that raises heart risk. It may help researchers understand who is most likely to develop these conditions and why, which could guide future prevention.
This study checks if a new investigational drug (MK-4646) changes how the body handles rosuvastatin, a common cholesterol-lowering medicine. It is for healthy people to see if the new drug is safe to take together.
This study compares two different ways of lowering cholesterol: a moderate statin (pitavastatin) plus another drug (ezetimibe) versus a stronger statin alone. The goal is to see which approach is safer regarding the risk of developing new diabetes.
Hear when a new Hyperlipidemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.